Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panobinostat + carboplatin + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Panobinostat + carboplatin + paclitaxel is a combination regimen under investigation for the treatment of advanced solid tumors. Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor that modulates gene expression and protein metabolism by inhibiting class I, II, and IV HDACs. This leads to cell cycle arrest and apoptosis in cancer cells. Carboplatin is a platinum-based chemotherapy agent that forms DNA adducts resulting in DNA damage and apoptosis. Paclitaxel stabilizes microtubules and prevents their depolymerization during cell division, causing mitotic arrest and subsequent cell death. The combination has shown synergistic antitumor effects in preclinical models as well as early-phase clinical trials for advanced solid tumors such as ovarian cancer and non-small-cell lung cancer[1][4][5][6]. The main dose-limiting toxicities are myelosuppression (neutropenia and thrombocytopenia), with other common side effects including diarrhea, fatigue, vomiting[1].
- Other names
- panobinostat + carboplatin + paclitaxel
02
Targets
DNAHDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)HDAC4TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on panobinostat + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panobinostat + carboplatin + paclitaxel.